Süreyya Yiğit Kaya, Yaşa Gül Mutlu, Ümit Yavuz Malkan, Özgür Mehtap, Fatma Keklik Karadağ, Gülten Korkmaz, Tuğrul Elverdi, Güray Saydam, Gülsüm Özet, Muhlis Cem Ar, Elif Melek, Senem Maral, Leylagül Kaynar, Ömür Gökmen Sevindik
BACKGROUND: Hairy cell leukemia (HCL) is a rare mature B-cell malignancy that is primarily treated with purine analogues. However, relapse remains a significant challenge, prompting the search for alternative therapies. The BRAF V600E mutation prevalent in HCL patients provides a target for treatment with vemurafenib. PATIENTS AND METHODS: This multicenter retrospective study included nine patients with relapsed/refractory (R/R) HCL from six different centers. Patient data included demographics, prior treatments, clinical outcomes, and adverse events...
March 29, 2024: Leukemia Research